$14.35
1.6%
Downside
Day's Volatility :8.16%
Upside
6.67%
70.17%
Downside
52 Weeks Volatility :83.77%
Upside
45.6%
Period | Cervomed Inc | Index (Russel 2000) |
---|---|---|
3 Months | -25.22% | 0.0% |
6 Months | -10.31% | 0.0% |
1 Year | 173.23% | 0.0% |
3 Years | 89.06% | -22.3% |
Market Capitalization | 122.4M |
Book Value | $6.06 |
Earnings Per Share (EPS) | 2.31 |
PE Ratio | 6.42 |
Wall Street Target Price | 58.25 |
Profit Margin | -52.24% |
Operating Margin TTM | -91.07% |
Return On Assets TTM | -90.48% |
Return On Equity TTM | 0.0% |
Revenue TTM | 9.7M |
Revenue Per Share TTM | 1.58 |
Quarterly Revenue Growth YOY | 91.2% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 2.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.63 |
EPS Estimate Next Year | -2.96 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | -0.45 |
What analysts predicted
Upside of 305.92%
Sell
Neutral
Buy
Cervomed Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cervomed Inc | 26.54% | -10.31% | 173.23% | 89.06% | 89.06% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cervomed Inc | 6.42 | 6.42 | NA | -1.63 | 0.0 | -0.9 | NA | 6.06 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cervomed Inc | Buy | $122.4M | 89.06% | 6.42 | -52.24% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Organization | Cervomed Inc |
Employees | 8 |
CEO | Dr. John J. Alam M.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$14.35
-3.24%
Keyarch Acquisition Corp
$14.35
-3.24%
Connexa Sports Technologies Inc
$14.35
-3.24%
Us Value Etf
$14.35
-3.24%
First Wave Biopharma Inc
$14.35
-3.24%
Global X Msci Next Emerging
$14.35
-3.24%
Fat Projects Acquisition Corp
$14.35
-3.24%
Capital Link Global Fintech
$14.35
-3.24%
Applied Uv Inc
$14.35
-3.24%